Carl Zeiss Meditec stock price target lowered to €47 at Berenberg

Berenberg has reduced its price target for Carl Zeiss Meditec AG (ETR:AFX) to €47.00 from €65.00, while maintaining a Hold rating, due to persistent post-pandemic recovery challenges. These include weak consumer confidence, volume-based procurement issues in China, and high U.S. interest rates impacting capital equipment spending, contributing to an approximately 80% share price decline since 2021. The firm specifically cited low visibility and unreliable market data in China as key concerns, indicating that recovery dynamics in the region remain a significant barrier to a more positive outlook.

Analysis

Berenberg has materially lowered its price target on Carl Zeiss Meditec AG (AFX) to €47.00 from €65.00, signaling deteriorating fundamentals, while maintaining a Hold rating. The downgrade reflects a confluence of persistent headwinds, including weak consumer confidence and the impact of high U.S. interest rates on capital equipment expenditures. A primary concern is the company's significant exposure to China, where it faces volume-based procurement challenges and what the analyst terms "low visibility on refractive surgical procedures and a lack of reliable market data." These factors have contributed to the stock's severe underperformance, with an approximate 80% decline from its 2021 peak. The continued Hold rating, despite the sharp target reduction and prevailing negative sentiment, suggests that while significant risks remain, much of the negative news may already be priced into the heavily discounted shares, with a lack of clear catalysts for a near-term re-rating.

Key Decisions for Investors

• Given the sustained Hold rating alongside a major price target cut, investors should view the stock as lacking near-term upside catalysts, with recovery contingent on improvements in key challenged markets.
• Monitor developments in China closely, as visibility on surgical procedure volumes and procurement policies are the most significant stated barriers to a more constructive outlook for the company.
• Investors should consider the stock's sensitivity to macroeconomic factors, particularly shifts in U.S. interest rates and changes in global consumer confidence, which directly impact capital equipment spending.
• The 80% share price decline since 2021 highs suggests significant distress is priced in, so existing holders may wait for signs of stabilization in China before rotating out of their positions at depressed levels.